Technical Analysis for XENE - Xenon Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade C 7.65 -2.05% -0.16
XENE closed down 2.05 percent on Friday, January 18, 2019, on 48 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Down
See historical XENE trend table...

Date Alert Name Type % Chg
Jan 18 1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Jan 18 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Jan 18 Outside Day Range Expansion 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 17 1,2,3 Pullback Bullish Bullish Swing Setup -2.05%
Jan 17 180 Bullish Setup Bullish Swing Setup -2.05%
Jan 17 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -2.05%
Jan 17 Narrow Range Bar Range Contraction -2.05%
Jan 17 Outside Day Range Expansion -2.05%
Jan 17 Wide Bands Range Expansion -2.05%

Older signals for XENE ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, is engaged in discovering and developing therapeutics for orphan indications. The company offers Glybera, a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Its product candidates in development comprise TV-45070, which is in Phase IIb clinical trials for the treatment of osteoarthritis of the knee; and in Phase II proof-of-concept clinical trials for the treatment of postherpetic neuralgia and Erythromelalgia. It is also developing TV-45070 for neuropathic pain indications; and GDC-0276 for the treatment of pain. The company's preclinical product candidates include a sodium channel inhibitor to treat DRAVET SYNDROME, an orphan disorder; XEN801, a stearoyl Co-A desaturase, an inhibitor for the treatment of acne; and small-molecule inhibitors for the treatment of cardiovascular disease. Xenon Pharmaceuticals Inc. has collaboration agreements with Teva Pharmaceutical Industries Ltd., Genentech, Inc., and Merck & Co., Inc. The company was founded in 1996 and is headquartered in Burnaby, Canada.
Is XENE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 15.92
52 Week Low 2.9
Average Volume 174,108
200-Day Moving Average 8.8542
50-Day Moving Average 7.5238
20-Day Moving Average 6.928
10-Day Moving Average 7.79
Average True Range 0.4716
ADX 31.44
+DI 24.2918
-DI 16.1632
Chandelier Exit (Long, 3 ATRs ) 7.225200000000001
Chandelier Exit (Short, 3 ATRs ) 6.8248
Upper Bollinger Band 8.7825
Lower Bollinger Band 5.0735
Percent B (%b) 0.69
BandWidth 53.536374
MACD Line 0.1405
MACD Signal Line -0.0132
MACD Histogram 0.1537
Fundamentals Value
Market Cap 137.67 Million
Num Shares 18 Million
EPS -1.66
Price-to-Earnings (P/E) Ratio -4.61
Price-to-Sales 65.85
Price-to-Book 1.07
PEG Ratio -0.05
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.13
Resistance 3 (R3) 8.16 8.02 8.05
Resistance 2 (R2) 8.02 7.90 8.01 8.02
Resistance 1 (R1) 7.84 7.83 7.77 7.81 8.00
Pivot Point 7.70 7.70 7.67 7.69 7.70
Support 1 (S1) 7.52 7.58 7.45 7.49 7.30
Support 2 (S2) 7.38 7.51 7.37 7.28
Support 3 (S3) 7.20 7.38 7.25
Support 4 (S4) 7.17